Home > News > Octoplus and Cytimmune give anticancer drug TNF new chance
May 28th, 2003
Octoplus and Cytimmune give anticancer drug TNF new chance
Abstract:
OctoPlus and CytImmune Sciences, Inc., announced today that they have entered into a collaboration agreement to develop a novel treatment for solid cancers. The treatment's active agent is the anticancer protein, tumor necrosis factor (TNF). (see 2nd story)
Source:
Octoplus
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||